Ibio Inc (IBIO)
NASDAQ:IBIO
Top Page
Ibio
(NASDAQ:IBIO)
Select Model
Select Model
Rating:46Neutral
Price Target:
$2.00
▼(-7.41% Downside)
Action:ReiteratedDate:04/09/26
The score is held down primarily by weak financial performance (minimal revenue, deep losses, and ongoing cash burn). Technicals are neutral-to-mixed and valuation is constrained by negative earnings, while corporate events provide some support from pipeline advancement and financing that extends runway.
Positive Factors
Clinical-stage advancement (IBIO-600)
Clearing regulatory and ethics hurdles to start a Phase 1 trial marks a structural shift from preclinical to clinical-stage operations. This milestone can materially de-risk the asset, enable human safety/PK data generation, increase partnerability, and create discrete value inflection points over the next 2-6 months.
Negative Factors
Minimal and declining revenue
Commercial scale is absent: near-zero, shrinking revenue indicates the company lacks product sales and is not self-sustaining. Persistent top-line weakness raises reliance on external capital or partnerships to fund development, limiting strategic independence and increasing execution risk across programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical-stage advancement (IBIO-600)
Clearing regulatory and ethics hurdles to start a Phase 1 trial marks a structural shift from preclinical to clinical-stage operations. This milestone can materially de-risk the asset, enable human safety/PK data generation, increase partnerability, and create discrete value inflection points over the next 2-6 months.
Read all positive factors
Ibio (IBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$74.61M
Dividend YieldN/A
Average Volume (3M)948.66K
Price to Earnings (P/E)―
Beta (1Y)1.52
Revenue Growth185.71%
EPS Growth79.03%
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding34,543,560
10 Day Avg. Volume505,043
30 Day Avg. Volume948,660
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.54
Price to Sales (P/S)20.03
P/FCF Ratio-0.52
Enterprise Value/Market Cap0.11
Enterprise Value/Revenue26.28
Enterprise Value/Gross Profit-34.28
Enterprise Value/Ebitda-0.37
Forecast
1Y Price Target
$5.50Price Target Upside154.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$200.00K
Ibio Business Overview & Revenue Model
Company Description
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead the...
How the Company Makes Money
null...
Ibio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 300.00K | 400.00K | 225.00K | 0.00 | 1.88M | 2.37M |
| Gross Profit | -230.00K | 400.00K | 225.00K | 0.00 | -1.91M | 909.00K |
| EBITDA | -21.46M | -17.04M | -14.02M | -27.85M | -25.72M | -28.55M |
| Net Income | -24.74M | -18.38M | -24.91M | -65.01M | -50.39M | -23.21M |
Balance Sheet | ||||||
| Total Assets | 64.39M | 23.18M | 28.73M | 41.21M | 99.41M | 146.97M |
| Cash, Cash Equivalents and Short-Term Investments | 52.70M | 8.58M | 14.21M | 7.33M | 33.52M | 96.97M |
| Total Debt | 2.45M | 3.51M | 4.46M | 17.07M | 25.77M | 32.72M |
| Total Liabilities | 7.83M | 8.30M | 7.41M | 25.83M | 35.92M | 38.40M |
| Stockholders Equity | 56.56M | 14.88M | 21.32M | 15.38M | 63.48M | 108.58M |
Cash Flow | ||||||
| Free Cash Flow | -19.19M | -15.32M | -18.76M | -36.17M | -45.13M | -35.23M |
| Operating Cash Flow | -18.63M | -15.30M | -18.55M | -30.44M | -37.80M | -30.06M |
| Investing Cash Flow | -24.45M | 742.00K | 906.00K | 7.01M | -5.13M | -26.48M |
| Financing Cash Flow | 64.73M | 8.93M | 24.49M | 2.30M | -5.80M | 78.83M |
Ibio Technical Analysis
Positive
2.16
Price Trends
2.30
Negative
2.07
Positive
1.48
Positive
Market Momentum
-0.07
Negative
49.74
Neutral
85.84
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBIO, the sentiment is Positive. The current price of 2.16 is above the 20-day moving average (MA) of 2.10, below the 50-day MA of 2.30, and above the 200-day MA of 1.48, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 49.74 is Neutral, neither overbought nor oversold. The STOCH value of 85.84 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBIO.
Ibio Risk Analysis
Ibio disclosed 59 risk factors in its most recent earnings report. Ibio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ibio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $74.61M | -5.32 | -71.26% | ― | 185.71% | 79.03% | |
44 Neutral | $238.44M | -0.12 | 506.72% | ― | ― | -323.61% | |
43 Neutral | $4.38M | -1.58 | -79.47% | ― | -99.97% | 35.59% | |
43 Neutral | $12.01M | -1.16 | -89.92% | ― | ― | 53.19% | |
41 Neutral | $4.74M | -0.54 | -1292.87% | ― | ― | 18.47% |
* Healthcare Sector Average
IBIO
Ibio
2.16
0.98
83.05%
NERV
Minerva Neurosciences
5.51
3.94
251.63%
PULM
Pulmatrix
1.20
-4.19
-77.74%
CMMB
Chemomab Therapeutics
1.67
-3.05
-64.62%
ASBP
Aspire Biopharma Holdings
1.06
-23.74
-95.73%
FBLG
FibroBiologics, Inc.
1.35
-18.25
-93.11%
Ibio Corporate Events
Business Operations and StrategyProduct-Related Announcements
iBio Advances to Clinical Stage With IBIO-600 Trial
Positive
Apr 8, 2026
On April 8, 2026, iBio announced it had received Clinical Trial Notification acknowledgement from Australia’s Therapeutic Goods Administration and ethics approval from a Human Research Ethics Committee, clearing the way for a first-in-human ...
Business Operations and StrategyProduct-Related Announcements
iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential
Positive
Mar 9, 2026
On March 9, 2026, iBio reported preclinical body composition data from an obese non-human primate study of IBIO-610, a potential first-in-class Activin E antibody for fat-selective weight loss and related cardiometabolic conditions. In this small,...
Business Operations and StrategyPrivate Placements and Financing
Ibio Ends At-The-Market Equity Offering Program
Negative
Feb 27, 2026
On February 23, 2026, Ibio terminated its At Market Issuance Sales Agreement with Chardan Capital Markets LLC and Craig-Hallum Capital Group LLC, which had been in place since July 3, 2024. As a result, the company also ended its at-the-market pro...
Business Operations and StrategyPrivate Placements and Financing
iBio Announces Private Placement to Fund Pipeline Expansion
Positive
Jan 12, 2026
On January 8, 2026, iBio, Inc. entered into a securities purchase agreement with existing, healthcare-focused institutional investors for an at-the-market private placement of 1,408,481 common shares and pre-funded warrants to purchase up to 9,653...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.